(Total Views: 471)
Posted On: 03/07/2021 8:44:57 PM
Post# of 153886
“The original protocol was submitted in February 2020 when much less was known about the disease.”
In typical NP fashion, he rushed the CD12 protocol: the protocol was developed and submitted before the data from the Montefiore patients was analyzed properly. Mortality, historically, is also a very risky endpoint, especially with a new virus and that’s been highlighted by mortality being removed as the primary endpoint in other COVId trials. Mortality would’ve been removed as CD12s primary endpoint as well had the 75% analysis was conducted.
I still believe leronlimab can reduce mortality, but it will require a larger, carefully planned and executed trial. That type of trial is not one CYDY is capable of right now with NP still at the helm and money tight. We may even see a reduction in mortality in the 140 patient critical trial, which will help support EUA/full approval.
In typical NP fashion, he rushed the CD12 protocol: the protocol was developed and submitted before the data from the Montefiore patients was analyzed properly. Mortality, historically, is also a very risky endpoint, especially with a new virus and that’s been highlighted by mortality being removed as the primary endpoint in other COVId trials. Mortality would’ve been removed as CD12s primary endpoint as well had the 75% analysis was conducted.
I still believe leronlimab can reduce mortality, but it will require a larger, carefully planned and executed trial. That type of trial is not one CYDY is capable of right now with NP still at the helm and money tight. We may even see a reduction in mortality in the 140 patient critical trial, which will help support EUA/full approval.
(1)
(1)
